Platelet-Like Particles Augment Natural Blood Clotting
|
By HospiMedica International staff writers Posted on 01 Oct 2014 |
A new class of synthetic particles could augment natural blood clotting for the emergency treatment of traumatic injuries, according to a new study.
Researchers at Georgia Institute of Technology (Atlanta, USA) and Emory University (Atlanta, GA, USA) developed the synthetic platelet-like particles (PLPs), from soft and deformable hydrogel precursor materials. The synthetic PLPs are bound to an antibody that has a high affinity to the polymerized form of fibrin, and a low affinity for fibrinogen. As a result, they are only activated when the body’s natural clotting process is triggered by thrombin-activated fibrin.
Testing done in animal models and in a simulated circulatory system suggest that the particles are effective at slowing bleeding, and can safely circulate in the bloodstream. The in vitro and in silico analyses also demonstrated that after clotting, the PLPs also actively collapse fibrin networks, an emergent behavior that mimics in vivo clot contraction. According to the researchers, the PLPs could offer doctors a new option for curbing surgical bleeding and addressing some clotting disorders without the need for transfusions of natural platelets. The study was published on September 7, 2014, in Nature Materials.
“When used by emergency medical technicians in the civilian world or by medics in the military, we expect this technology could reduce the number of deaths from excessive bleeding,” said lead author Ashley Brown, PhD, of the Georgia Tech school of chemistry and biochemistry. “If EMTs and medics had particles like these that could be injected and then go specifically to the site of a serious injury, they could help decrease the number of deaths associated with serious injuries.”
“For a patient with insufficient platelets due to bleeding or an inherited disorder, physicians often have to resort to platelet transfusions, which can be difficult to obtain,” added co-author Wilbur Lam, MD, of the Emory school of medicine department of pediatrics. “These particles could potentially be a way to obviate the need for a transfusion. Though they don’t have all the assets of natural platelets, a number of intriguing experiments have shown that the particles help augment the clotting process.”
Related Links:
Georgia Institute of Technology
Emory University
Researchers at Georgia Institute of Technology (Atlanta, USA) and Emory University (Atlanta, GA, USA) developed the synthetic platelet-like particles (PLPs), from soft and deformable hydrogel precursor materials. The synthetic PLPs are bound to an antibody that has a high affinity to the polymerized form of fibrin, and a low affinity for fibrinogen. As a result, they are only activated when the body’s natural clotting process is triggered by thrombin-activated fibrin.
Testing done in animal models and in a simulated circulatory system suggest that the particles are effective at slowing bleeding, and can safely circulate in the bloodstream. The in vitro and in silico analyses also demonstrated that after clotting, the PLPs also actively collapse fibrin networks, an emergent behavior that mimics in vivo clot contraction. According to the researchers, the PLPs could offer doctors a new option for curbing surgical bleeding and addressing some clotting disorders without the need for transfusions of natural platelets. The study was published on September 7, 2014, in Nature Materials.
“When used by emergency medical technicians in the civilian world or by medics in the military, we expect this technology could reduce the number of deaths from excessive bleeding,” said lead author Ashley Brown, PhD, of the Georgia Tech school of chemistry and biochemistry. “If EMTs and medics had particles like these that could be injected and then go specifically to the site of a serious injury, they could help decrease the number of deaths associated with serious injuries.”
“For a patient with insufficient platelets due to bleeding or an inherited disorder, physicians often have to resort to platelet transfusions, which can be difficult to obtain,” added co-author Wilbur Lam, MD, of the Emory school of medicine department of pediatrics. “These particles could potentially be a way to obviate the need for a transfusion. Though they don’t have all the assets of natural platelets, a number of intriguing experiments have shown that the particles help augment the clotting process.”
Related Links:
Georgia Institute of Technology
Emory University
Latest Critical Care News
- AI Stethoscope Spots Heart Valve Disease Earlier Than GPs
- Bioadhesive Patch Eliminates Cancer Cells That Remain After Brain Tumor Surgery
- Wearable Patch Provides Up-To-The-Minute Readouts of Medication Levels in Body
- New Spray-Mist Device Delivers Antibiotics Directly into Infected Tissue
- Living Implant Could End Daily Insulin Injections
- Intelligent Camera System Continuously Monitors Premature Babies in NICU
- Intranasal Spray to Prevent Illnesses from Respiratory Viruses
- Gut Bacteria from Amphibians and Reptiles Show Complete Tumor Elimination
- High-Dose Inhaled Nitric Oxide Emerges as Promising Antimicrobial Therapy
- AI Risk Prediction Tool Improves Treatment of Cancer Patients after Heart Attack
- Glowing Bacterial Sensors Could Improve Detection of Gut Illness
- Innovative ‘Poop Pills’ Dramatically Improve Cancer Treatment

- New Nanomaterial Kills Cancer Cells While Sparring Healthy Tissues
- AI Model Accurately Predicts Neurological Recovery After Cardiac Arrest
- Battery-Free Nano-Sensors Pave Way for Next-Generation Wearables
- Imaging Technology Detects Early Signs of Cardiovascular Risk Through Skin
Channels
Artificial Intelligence
view channelSurgical Techniques
view channel
Neural Device Regrows Surrounding Skull After Brain Implantation
Placing electronic implants on the brain typically requires removing a portion of the skull, creating challenges for long-term access and safe closure. Current methods often involve temporarily replacing... Read more
Surgical Innovation Cuts Ovarian Cancer Risk by 80%
Ovarian cancer remains the deadliest gynecological cancer, largely because there is no reliable screening test, and most cases are diagnosed at advanced stages. Thousands of patients die each year as treatment... Read morePatient Care
view channel
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
VR Training Tool Combats Contamination of Portable Medical Equipment
Healthcare-associated infections (HAIs) impact one in every 31 patients, cause nearly 100,000 deaths each year, and cost USD 28.4 billion in direct medical expenses. Notably, up to 75% of these infections... Read more
Portable Biosensor Platform to Reduce Hospital-Acquired Infections
Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read moreFirst-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read moreHealth IT
view channel
EMR-Based Tool Predicts Graft Failure After Kidney Transplant
Kidney transplantation offers patients with end-stage kidney disease longer survival and better quality of life than dialysis, yet graft failure remains a major challenge. Although a successful transplant... Read more
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read moreBusiness
view channel
Medtronic to Acquire Coronary Artery Medtech Company CathWorks
Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Medtronic and Mindray Expand Strategic Partnership to Ambulatory Surgery Centers in the U.S.
Mindray North America and Medtronic have expanded their strategic partnership to bring integrated patient monitoring solutions to ambulatory surgery centers across the United States. The collaboration... Read more
FDA Clearance Expands Robotic Options for Minimally Invasive Heart Surgery
Cardiovascular disease remains the world’s leading cause of death, with nearly 18 million fatalities each year, and more than two million patients undergo open-heart surgery annually, most involving sternotomy.... Read more







